BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,564,700 | +84341.4% | 41,460 | +1.9% | 0.05% | -12.9% |
| Q2 2023 | $1,853 | +14.5% | 40,672 | +1.9% | 0.06% | +3.3% |
| Q1 2023 | $1,618 | -19.8% | 39,903 | +0.8% | 0.06% | -25.0% |
| Q4 2022 | $2,018 | -99.9% | 39,595 | +0.4% | 0.08% | -11.1% |
| Q3 2022 | $2,123,000 | -11.5% | 39,422 | +5.5% | 0.09% | -10.9% |
| Q2 2022 | $2,400,000 | -3.0% | 37,371 | +17.1% | 0.10% | 0.0% |
| Q1 2022 | $2,475,000 | -4.7% | 31,914 | +5.5% | 0.10% | -3.8% |
| Q4 2021 | $2,596,000 | +13.8% | 30,237 | +6.6% | 0.10% | -1.9% |
| Q3 2021 | $2,281,000 | -3.2% | 28,365 | -3.1% | 0.11% | -3.6% |
| Q2 2021 | $2,357,000 | -6.4% | 29,282 | -1.9% | 0.11% | -9.8% |
| Q1 2021 | $2,518,000 | +0.6% | 29,858 | -4.2% | 0.12% | -4.7% |
| Q4 2020 | $2,502,000 | +5.3% | 31,177 | +5.5% | 0.13% | -12.2% |
| Q3 2020 | $2,376,000 | -2.6% | 29,547 | +4.3% | 0.15% | -14.0% |
| Q2 2020 | $2,439,000 | -13.8% | 28,327 | -18.8% | 0.17% | -11.9% |
| Q1 2020 | $2,831,000 | +28.9% | 34,869 | +32.8% | 0.19% | +21.2% |
| Q4 2019 | $2,196,000 | -4.0% | 26,266 | +0.4% | 0.16% | -12.1% |
| Q3 2019 | $2,288,000 | -36.8% | 26,162 | -40.8% | 0.18% | +13.8% |
| Q2 2019 | $3,620,000 | +113.6% | 44,190 | +112.0% | 0.16% | -2.4% |
| Q1 2019 | $1,695,000 | +19.6% | 20,840 | -3.2% | 0.16% | +5.8% |
| Q4 2018 | $1,417,000 | -13.1% | 21,527 | +1.7% | 0.16% | -0.6% |
| Q3 2018 | $1,631,000 | +5.6% | 21,159 | +1.2% | 0.16% | -1.3% |
| Q2 2018 | $1,544,000 | -8.5% | 20,916 | -19.3% | 0.16% | +9.7% |
| Q1 2018 | $1,687,000 | -15.6% | 25,934 | -16.1% | 0.14% | +1.4% |
| Q4 2017 | $1,998,000 | +6.3% | 30,913 | +3.2% | 0.14% | 0.0% |
| Q3 2017 | $1,879,000 | -0.7% | 29,949 | -4.2% | 0.14% | 0.0% |
| Q2 2017 | $1,893,000 | +17.1% | 31,268 | +0.3% | 0.14% | +14.5% |
| Q1 2017 | $1,616,000 | +2.6% | 31,164 | -12.3% | 0.12% | +9.7% |
| Q4 2016 | $1,575,000 | -20.4% | 35,522 | -14.5% | 0.11% | -14.4% |
| Q3 2016 | $1,979,000 | -6.8% | 41,568 | -11.5% | 0.13% | -3.6% |
| Q2 2016 | $2,124,000 | +2.7% | 46,963 | -6.7% | 0.14% | +8.7% |
| Q1 2016 | $2,068,000 | +30.5% | 50,334 | +21.1% | 0.13% | +7.7% |
| Q4 2015 | $1,585,000 | +28.9% | 41,549 | +11.0% | 0.12% | +10.4% |
| Q3 2015 | $1,230,000 | -52.1% | 37,433 | +1.9% | 0.11% | -49.3% |
| Q2 2015 | $2,568,000 | +2.6% | 36,723 | +0.6% | 0.21% | +3.0% |
| Q1 2015 | $2,502,000 | -15.3% | 36,520 | -9.4% | 0.20% | -6.9% |
| Q4 2014 | $2,953,000 | -2.3% | 40,289 | -4.4% | 0.22% | -1.8% |
| Q3 2014 | $3,024,000 | -8.7% | 42,140 | -6.4% | 0.22% | -7.1% |
| Q1 2014 | $3,313,000 | +6.3% | 45,026 | +0.5% | 0.24% | +4.8% |
| Q4 2013 | $3,116,000 | +5.2% | 44,806 | -0.6% | 0.23% | -4.6% |
| Q3 2013 | $2,962,000 | – | 45,085 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |